Business Context and Reporting Period
This Form 8-K is filed by Ekso Bionics Holdings, Inc. (not Chronoscale Holdings Corp) on January 4, 2024. The report provides preliminary, unaudited financial results for the quarter and fiscal year ended December 31, 2023. The company operates in the medical technology sector, specifically developing robotic exoskeletons.
Key Financial Metrics
| Metric | Q4 2023 (Estimated) | Q4 2022 | FY 2023 (Estimated) | FY 2022 |
|---|---|---|---|---|
| Total Revenue | $4.7M - $4.9M | $3.6M | $18.1M - $18.3M | $12.9M |
| Cash Used in Operations | $1.7M | $3.6M | N/A | N/A |
| Cash Balance (as of Dec 31) | $8.6M | $20.5M | $8.6M | $20.5M |
| Net Profit/Loss | Not provided | Not provided | Not provided | Not provided |
| Debt | Not provided | Not provided | Not provided | Not provided |
Note: The filing text does not provide clear values for net profit, operating margins, or specific debt obligations.
Material Changes vs. Prior Period
- Revenue Growth: Q4 2023 revenue is estimated to be approximately 31% to 36% higher than Q4 2022. Full-year 2023 revenue is estimated to be approximately 40% to 42% higher than 2022.
- Cash Flow Improvement: Cash used in operations for Q4 2023 ($1.7M) decreased significantly compared to Q4 2022 ($3.6M), indicating improved operational efficiency or reduced burn rate.
- Liquidity Decline: Total cash and cash equivalents decreased by approximately $11.9 million (from $20.5M to $8.6M) year-over-year.
Guidance, Outlook, and Risks
Management Commentary: The financial data presented is preliminary and unaudited. Management has not completed the financial statement reporting process, and the independent registered accounting firm has not audited these figures.
Risks and Contingencies:
- Preliminary Nature: Final financial statements may require material adjustments during the quarter-end closing procedures.
- Forward-Looking Statements: Estimates are based on current projections and assumptions. Actual results may differ materially due to risks described in the company's Form 10-K and 10-Q filings.
- Non-Filing Status: The information in Item 2.02 is furnished and not deemed "filed" under the Exchange Act, limiting its legal incorporation into other filings.
Investor Verification Checklist
- Verify the final audited revenue figures in the upcoming Form 10-K to confirm if they fall within the estimated ranges ($4.7M-$4.9M for Q4; $18.1M-$18.3M for FY).
- Review the full Form 10-K for details on net loss, operating expenses, and specific debt covenants not disclosed in this 8-K.
- Assess the sustainability of the reduced cash burn rate ($1.7M vs $3.6M) in the context of the company's remaining cash balance ($8.6M).
- Confirm the company's runway and capital requirements given the significant year-over-year decline in cash reserves.